2-甲基-5-苯基吡啶 | 3256-88-0

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-甲基-5-苯基吡啶
• 英文名称: 5-phenyl-2-picoline
• 英文别名: 2-methyl-5-phenylpyridine；3-phenyl-6-methyl pyridine
• CAS: 3256-88-0
• 化学式: C₁₂H₁₁N
• mdl: MFCD00129776
• 分子量: 169.226
• InChiKey: JXNAIOCJWBJGFQ-UHFFFAOYSA-N

物化性质

• 沸点：
  288.52°C (rough estimate)
• 密度：
  1.0590
• 保留指数：
  1513

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-甲基-5-苯基吡啶 在 双氧水 、 三乙胺 、 三氯氧磷 作用下， 以 二氯甲烷 、 溶剂黄146 为溶剂， 生成 2-(氯甲基)-5-苯基吡啶
  参考文献：
  名称：

  Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816

  摘要：

  Thiopyrano[2,3,4-c,d]indoles are a new class of 5-lipoxygenase (5-LO) inhibitors. SAR studies have demonstrated that the thiopyran ring, the 5-phenylpyridine substituent, and an acidic functional group on a four-carbon C-2 side chain are all required for optimal inhibitor potency. In contrast, the indolic nitrogen may be substituted with a variety of lipophilic groups. As a result of the SAR investigation, 44 (L-691,816; 5-[3-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]-2,2-dimethylpropyl]-1H-tetrazole) has been identified as a potent inhibitor of the 5-LO reaction both in vitro and in a range of in vivo models. Compound 44 inhibits 5-HPETE production by both rat and human 5-LO and LTB4 synthesis in human PMN leukocytes (IC50s 16,75, and 10 nM, respectively). The mechanism of inhibition of 5-LO activity by compound 44 appears to involve the formation of a reversible deadend complex with the enzyme and does not involve reduction of the nonheme iron of 5-LO. Compound 44 is highly selective for 5-LO when compared to the inhibition of human FLAP, porcine 12-LO, and also ram seminal vesicle cyclooxygenase. In addition, 44 is orally active in a rat pleurisy model (inhibition of LTB4, ED50 = 1.9 mg/kg; 8 h pretreatment) as well as in the hyperreactive rat model of antigen-induced dyspnea (ED50 = 0.1 mg/kg;2-h pretreatment). Excellent functional activity was also observed in both the conscious allergic monkey and sheep models of asthma. In the latter case, the functional activity observed correlated with the inhibition of urinary LTE4 excretion.

  DOI：

  10.1021/jm00071a008
• 作为产物：
  描述：

  3-羟基-6-甲基吡啶 在 硫酰氟 、 palladium diacetate 、 三乙胺 、 三苯基膦 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 36.0h， 生成 2-甲基-5-苯基吡啶
  参考文献：
  名称：

  镍和钯催化的芳基氟磺酸盐与芳基硼酸的磺酰氟催化偶联

  摘要：

  本文报道了芳基氟磺酸盐和芳基硼酸的镍和钯催化的交叉偶联的实例。这些反应在温和条件下以良好的收率产生，并具有优异的官能团相容性，采用Pd（OAc）2和廉价的PPh 3或廉价且易于获得的NiCl 2（PCy 3）2。重要地，描述了通过与硫酰氟和碱反应并随后在单个罐中交叉偶联形成联芳基而将苯酚衍生物原位转化为相应的氟代磺酸芳基酯。这些方法学中报道的廉价的硫酰氟和有效的催化剂的结合将使制药和农业化学过程中苯酚的经济Suzuki偶联成为可能。

  DOI：

  10.1021/acscatal.5b01021
• 作为试剂：
  描述：

  3-苯基吡啶 、 水 、 十二烷醇 在 镍 水 、 正己烷 、 盐酸 、 2-甲基-5-苯基吡啶 、 二氯甲烷 、 NH4OAc 、 magnesium sulfate 、 crude residue 作用下， 25.0~200.0 ℃ 、1.78 kPa 条件下， 反应 6.0h， 生成 2-甲基-5-苯基吡啶
  参考文献：
  名称：

  Aryl thiopyrano[2,3,4-C,D]indoles as inhibitors of leukotriene

  摘要：

  公式为I的化合物：##STR1##是5-脂氧合酶抑制剂和白三烯生物合成抑制剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。它们还可用于治疗心绞痛、脑血管痉挛、肾小球肾炎、肝炎、内毒素血症、牛皮癣、葡萄膜炎和移植排斥，并预防动脉粥样硬化斑块的形成。

  公开号：

  US05314900A1

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：DE PERETTI Danielle

  公开号：US20110065727A1

  公开（公告）日：2011-03-17

  Compounds of formula (I): wherein R, R 1 , R 2 , R 3 , R 4 and X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.

  式（I）的化合物： 其中R、R1、R2、R3、R4和X如披露中所定义，或其酸盐，以及其治疗用途和合成过程。
• Pyridyl dialkanoic acids and their use as medicaments
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0318083A3

  公开（公告）日：1990-12-05

  Compounds having the formula. are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.

  具有以下化学式的化合物是白三烯拮抗剂和白三烯生物合成抑制剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。
• PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS
  申请人：Hadida Ruah Sara Sabina

  公开号：US20120196869A1

  公开（公告）日：2012-08-02

  The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  这项发明涉及对离子通道具有抑制作用的吡咯吡嘧啶-螺环哌啶酰胺化合物。该发明还提供了包括该发明化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病的方法。

表征谱图